Piramal Consumer Healthcare targets $200 million revenue by FY30.

Piramal Consumer Healthcare, part of Piramal Pharma, is targeting revenues of over $200 million by FY30, driven by the expansion of its power brands and a strong focus on innovation and market reach.

The company plans to accelerate growth across key brands such as skincare label Lacto Calamine and babycare brand Little’s through new product launches and wider distribution. With skincare routines evolving in India, Lacto Calamine is also expanding its portfolio to broaden consumer appeal.

Sai Ramana Ponugoti, CEO of Piramal Consumer Healthcare, told businessline that the company has delivered high double-digit growth so far this year and has outpaced its revenue performance from the previous fiscal. “We have a clear roadmap to double our business by FY30 while delivering double-digit EBITDA margins. Our strategy will focus on maximising revenues, driving innovation, and investing behind our power brands,” he said.

Innovation remains a key growth driver for the company. Over the past 12 months, Piramal Consumer Healthcare has launched a range of new products, with new product development (NPD) now contributing more than 11 per cent of overall revenues. The company aims to further increase this share to support its profitable growth ambitions.

Ponugoti added that one of the ways the company is accelerating innovation is by launching quick-commerce-first products to better understand consumer preferences and rapidly scale successful offerings.